NASDAQ · Shell Companies · USD

Drugs Made In America Acquisition II Corp. (DMII) Stock Analysis

Drugs Made In America Acquisition II Corp. (DMII) is a Shell Companies stock listed on NASDAQ and quoted in US Dollar.

DMII

$10.17

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DMII with… →

DMII Key Statistics

As of Sep 4, 2026

Trading

Open: $10.17
Previous Close: $10.17
52-Week Range: 9.86–10.21
Volume: 900

Valuation

Market Cap: $647.83M
P/E Ratio: 35.07
EPS (ttm): 0.29

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): $4.19M
Profit margin: 0.00%
Shares Outstanding: 63.70M

Dividend and dates

Avg Volume: 72.65K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DMII Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	+2.73%
2025 (partial year)	+0.20%

As of September 4, 2026.

DMII Valuation vs Shell Companies Median

Median of 587 stocks

Metric	DMII	Shell Companies median	vs median
P/E	35.07	45.20	22% below
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 587 Shell Companies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Drugs Made In America Acquisition II Corp. (DMII) carries a market capitalisation of $647.83M. The company sits in the Financial Services sector, in the Shell Companies industry.

The 52-week range on file runs from $9.86 to $10.21. DMII last closed at $10.17 on September 4, 2026. The close was unchanged from the previous session. The latest close sits 3.14% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. Net income for the same year was $4.19M. Profit margin runs at 0%. Earnings per share on a trailing basis come to 0.29.

Valuation Assessment

The trailing P/E ratio stands at 35.07. That is 22.41% below the Shell Companies median of 45.2. The medians here are taken across 587 Shell Companies companies that report the metric.

The stored price history starts on December 3, 2025, and the total return since then is +2.94%.

Growth & Income

No dividend is on file for DMII.

So far in 2026 the price is +2.73%.

Peer Comparison

Drugs Made In America Acquisition II Corp. (DMII) operates in the Shell Companies industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Drugs Made In America Acquisition II Corp.	DMII	$647.83M	35.1
Churchill Capital Corp XI	CCXI	$746.38M	—
Churchill Capital Corp X	CCCX	$711.00M	—
Bain Capital GSS Investment Corp.	BCSS	$602.40M	—

The Shell Companies industry average P/E ratio is 45.2x. Drugs Made In America Acquisition II Corp. trades at a P/E of 35.1.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Shell Companies Stocks

CCXI

Churchill Capital Corp XI

$746.38M

CCCX

Churchill Capital Corp X

$711.00M

BCSS

Bain Capital GSS Investment Corp.

$602.40M

EVAC

EQV Ventures Acquisition Corp. II

$602.01M

CXII

Churchill Capital Corp XII

$594.94M

CEPF

Cantor Equity Partners IV, Inc.

$594.36M

View all Shell Companies stocks →

Popular Financial Services Stocks

BRK-B

Berkshire Hathaway Inc.

$1.08T

JPM

JPMorgan Chase & Co.

$953.33B

Visa Inc.

$700.27B

Mastercard Incorporated

$507.39B

BAC

Bank of America Corporation

$438.31B

View all Financial Services stocks →

About Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.